Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
1 clinical trials · Condition
◉ Watch Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
| Record | Firm | Date |
|---|---|---|
| An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer (NCT05356351) | Tianjin Medical University Cancer Institute and Hospital | 2022-05-01 |
Track Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance automatically
Every clearance here is in the API, with alerts when new ones post.